FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)										1				
Name and Address of Reporting Person * Li Kecheng				2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [EKSO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201				3. Date of Earliest Transaction (Month/Day/Year) 07/23/2020						Office	r (give title beld	ow)0	Other (specify l	pelow)		
(Street) RICHMOND, CA 94804				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Year		if Coo	Code (Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D)	Beneficia	nt of Securities ally Owned Following Transaction(s) and 4)		Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						C	ode	V	Amour	(A) or (D)	Price				(I) (Instr. 4)	
Common Stock 07/23/2020		A 7,383 A \$0		9,143 (2)		D										
			r each class of secur	Derivativ	e Secur	rities A	cquir	Pers cont the f	ons what in the constant in th	no respo n this fo splays a of, or Be	rm ar curre	e not requently valid	OMB con	formation spond unle trol numbe	ss	1474 (9-02)
1. Title of	2.	3. Transaction	· · · · · · · · · · · · · · · · · · ·	<i>e.g.</i> , puts 4.	, calls,	warran 5.	its, op	1 – 1	, conver ate Exer	tible secu cisable) Γitle and	8. Price of	9. Number o	of 10.	11. Natur
Derivative Security	Conversion or Exercise Price of Derivative Security		Year) Execution Da	te, if Transaction Code (Instr. 8)		n Num of Deriv Secu Acqu (A) of Disp of (D (Instr	Number		and Expiration Date (Month/Day/Year)		Am Und Sec	nount of derlying curities str. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	hip of Indirect Beneficia Ownershi (Instr. 4)
				Co	ode V	(A)	(D)	Date Exer	e rcisable	Expiration Date	Tit	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Li Kecheng C/O EKSO BIONICS HOLDINGS, INC. 1414 HARBOUR WAY SOUTH, SUITE 1201 RICHMOND, CA 94804	X					

Signatures

/s/ John F. Glenn, as attorney-in-fact for Kecheng Li	07/27/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The grant consists of RSUs that fully vest one year from the date of grant, or July 23, 2021.
- (2) After taking into account the 1-for-15 reverse stock split effective March 24, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.